Drugs / Prazosin
last change Jun 2026 re-read 9 days ago

Prazosin

Developed for
post-traumatic stress disorder · alcohol dependence · alcohol-related disorders · hypertensive disorder · sleep disorder · acute stress disorder · alcohol abuse · alcohol withdrawal
+24 more · Alzheimer disease · amphetamine abuse · anxiety · autonomic dysreflexia · chronic hepatitis C virus infection · cirrhosis of liver · COVID-19 · parasomnia, sleep terrors type · portal hypertension · resistant hypertension · urinary tract obstruction · bulimia nervosa · cocaine dependence · combat disorder · disruptive behavior disorder · insomnia · manic bipolar affective disorder · migraine disorder · nicotine dependence · scorpion envenomation · substance-related disorder · traumatic brain injury · traumatic encephalopathy · urolithiasis
Investigated by
Seattle Institute for Biomedical and Clinical Research · VA Puget Sound Health Care System · National Institute on Alcohol Abuse and Alcoholism (NIAAA) · Pfizer · US Department of Veterans Affairs · University of Wisconsin, Madison
+33 more · VA Office of Research and Development · Augusta University · Kinnov Therapeutics · United States Department of Defense · University of Washington · Yale University · Assistance Publique - Hôpitaux de Paris · Brian J Lipworth · Cedars-Sinai Medical Center · Centre for Addiction and Mental Health · ECSOR · Fast Grants · French National Agency for Research on AIDS and Viral Hepatitis · Hospices Civils de Lyon · Johns Hopkins University · Madigan Army Medical Center · Ministry of Health, France · National Institute of Mental Health (NIMH) · National Institute of Neurological Disorders and Stroke (NINDS) · National Institute on Aging (NIA) · National Institute on Drug Abuse (NIDA) · Ontario Lung Association · Rainier Associates · Sant Pau Research Institute · Sohag University · The University of Texas at Arlington · University of Arkansas · University of British Columbia · University of Manitoba · University of Maryland, Baltimore · University of Pittsburgh · VA Mental Illness Research, Education and Clinical Centers · Vanderbilt University

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) MINIPRESS — 1976-06-23 fda.gov ↗

Trials 40

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 15 trials
Phase 1 NCT07231978 Nov 2025 → Apr 2026 — Pfizer Completed No outcome recorded
Phase 1 NCT06147622 Apr → Jul 2024 alcohol-related disorders Kinnov Therapeutics Completed No outcome recorded
Phase 1 NCT03894345 May 2019 → Dec 2023 anxiety University of Manitoba Suspended No outcome recorded
Phase 1 NCT01999530 Nov 2013 → Aug 2016 — Centre for Addiction and Mental Health Completed No outcome recorded
Phase 1 NCT00223717 Jan 2001 → Jan 2017 hypertensive disorder Vanderbilt University Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT02966340 Nov 2016 → Mar 2018 alcohol dependence University of Wisconsin, Madison Completed No outcome recorded
Phase 212 trials · 2 met primary
Phase 2 NCT06629077 Feb 2026 → May 2027 expected cerebrovascular disorder University of Wisconsin, Madison Recruiting No outcome recorded
Phase 2 NCT06629090 Dec 2025 → May 2027 expected cerebrovascular disorder University of Wisconsin, Madison Recruiting No outcome recorded
Phase 2 NCT04793685 Jul 2021 → Jan 2026 alcohol withdrawal Yale University Completed No outcome recorded
Phase 2 NCT04365257 May 2020 → Mar 2022 COVID-19 Johns Hopkins University Terminated No outcome recorded Stop: Enrollment
Phase 2 NCT04108104 Nov 2019 → Oct 2021 alcohol dependence Kinnov Therapeutics Completed Met primary
Phase 2 NCT03045016 Apr 2017 → Mar 2020 acute stress disorder Hospices Civils de Lyon Completed No outcome recorded
Phase 2 NCT02431936 Apr 2015 → Apr 2019 hypertensive disorder Augusta University Completed No outcome recorded
Phase 2 NCT02322047 Mar 2015 → Oct 2018 alcohol-related disorders, post-traumatic stress disorder Seattle Institute for Biomedical and Clinical Research Completed No outcome recorded
Phase 2 NCT01178138 Dec 2009 → Jun 2013 amphetamine abuse University of Arkansas Completed No outcome recorded
Phase 2 NCT01518972 Sep 2009 → Jun 2012 alcohol abuse, post-traumatic stress disorder Seattle Institute for Biomedical and Clinical Research Completed No outcome recorded
Phase 32 trials
Phase 3 NCT03539614 Jun 2018 → Jan 2026 overdue post-traumatic stress disorder VA Office of Research and Development Active not recruiting No outcome recorded
Phase 3 NCT00744055 Jan 2009 → Oct 2014 alcohol dependence, post-traumatic stress disorder Yale University Completed No outcome recorded
Phase 410 trials
Phase 4 NCT07862712 Mar 2027 → Dec 2031 expected metabolic syndrome X, post-traumatic stress disorder VA Office of Research and Development Not yet recruiting No outcome recorded
Phase 4 NCT06287905 Feb 2023 → Jul 2024 — Sohag University Unknown No outcome recorded
Phase 4 NCT04721353 Nov 2020 → Dec 2024 cannabis dependence, post-traumatic stress disorder VA Puget Sound Health Care System Completed No outcome recorded
Phase 4 NCT03221751 Dec 2016 → Jan 2023 dementia VA Office of Research and Development Terminated No outcome recorded
Phase 4 NCT02965027 Nov 2016 → May 2023 — Seattle Institute for Biomedical and Clinical Research Completed No outcome recorded
Phase 4 NCT02539810 Sep 2015 → Dec 2016 renal artery atheroma, resistant hypertension Assistance Publique - Hôpitaux de Paris Terminated No outcome recorded
Phase 4 NCT02199652 Mar 2014 → Sep 2017 parasomnia, sleep terrors type, post-traumatic stress disorder Augusta University Completed No outcome recorded
Phase 4 NCT00487032 May 2008 → May 2009 allergic rhinitis Brian J Lipworth Completed No outcome recorded
Phase 4 NCT00108420 Oct 2003 → Mar 2007 post-traumatic stress disorder US Department of Veterans Affairs Completed No outcome recorded
Phase 4 NCT00450164 Nov 2000 → Jun 2004 cirrhosis of liver, portal hypertension Sant Pau Research Institute Completed No outcome recorded
Phase not applicable10 trials · 2 met primary
— NCT03416569 Mar 2018 → Jan 2019 — University of Maryland, Baltimore Withdrawn No outcome recorded Stop: Business
— NCT01923129 Nov 2012 → Nov 2017 urinary tract obstruction Cedars-Sinai Medical Center Completed Met primary
— NCT01637584 Apr 2010 → Nov 2012 post-traumatic stress disorder University of Pittsburgh Completed No outcome recorded
— NCT01126099 Mar 2010 → Mar 2014 Alzheimer disease Seattle Institute for Biomedical and Clinical Research Completed No outcome recorded
— NCT00890643 Dec 2009 → Jun 2011 post-traumatic stress disorder US Department of Veterans Affairs Withdrawn No outcome recorded
— NCT00175682 Dec 2004 → Jul 2011 autonomic dysreflexia University of British Columbia Completed No outcome recorded
— NCT00202449 Jul 2004 → Feb 2008 post-traumatic stress disorder, sleep disorder Seattle Institute for Biomedical and Clinical Research Terminated No outcome recorded Stop: Enrollment
— NCT00261729 Jul 2004 → Aug 2007 post-traumatic stress disorder, sleep disorder US Department of Veterans Affairs Completed Met primary
— NCT00174551 Nov 2003 → Nov 2005 post-traumatic stress disorder Rainier Associates Unknown No outcome recorded
— NCT00183430 Oct 2003 → May 2009 post-traumatic stress disorder, sleep disorder, initiating and maintaining sleep Seattle Institute for Biomedical and Clinical Research Terminated No outcome recorded Stop: Enrollment
Comparator or background therapy24 trials
Phase 0 NCT02193256 Comparator Jul 2014 → Jan 2015 alcohol-related disorders Yale University Completed No outcome recorded
Phase 1 NCT05189977 Comparator Sep 2022 → Aug 2023 post-traumatic stress disorder Otsuka Pharmaceutical Development & Commercialization, Inc. Terminated No outcome recorded
Phase 1 NCT03010995 Comparator Mar → Jul 2018 cardiovascular disorder, poisoning University of Louisville Withdrawn No outcome recorded Stop: Business
Phase 1/2 NCT02266329 Comparator Jan 2016 → May 2023 combat disorder, migraine disorder, traumatic brain injury, traumatic encephalopathy VA Office of Research and Development Completed No outcome recorded
Phase 1/2 NCT00585780 Comparator Sep 2009 → Aug 2018 alcohol dependence Yale University Completed No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2023-03-01 Alembic Pharmaceuticals Ltd. Regulatory 8th March, 2023, Vadodara, India alembicpharmaceuticals.com ↗
Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Prazosin Hydrochloride Capsules USP, 1 mg, 2 mg, and 5 mg.

All press releases naming this drug 1 release

DateIssuerRelease

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 66 sources stand behind the page.

FieldValueCited text
Known as prazosin “Prazosin and cyproheptadine in combination in the treatment of alcohol use disorder: A randomized, double-blind, placebo-controlled trial.” PMID 38597214 ↗ Apr 2024
64

“Prazosin is the first choice agent in this Arm” NCT01542372 ↗

“doxazosin, prazosin, terazosin, clonidine” NCT00684489 ↗

“prazosin 5 mg/d” NCT02539810 ↗

“prazosin” NCT00990106 ↗

NCT03710642 ↗

NCT02966340 ↗

NCT02193256 ↗

NCT03221751 ↗

NCT02266329 ↗

NCT00990106 ↗

Show 54 more sources

Known as ALPRESS LP “Prazosin, ALPRESS® LP 2,5 et 5 mg” NCT03045016 ↗
Known as Minipress “The investigators hypothesize that Minipress® (prazosin HCL), a blood pressure medication, which has a slower and less abrupt suppressive effect on blood pressure, would be a...” NCT00175682 ↗
Known as Prazosin HCl “The investigators hypothesize that Minipress® (prazosin HCL), a blood pressure medication, which has a slower and less abrupt suppressive effect on blood pressure, would be a...” NCT00175682 ↗
1

“Participants will receive a single dose of Prazosin HCl in 4 treatments.” NCT07231978 ↗

Known as prazosin hydrochloride “Prazosin hydrochloride (HCl) is a medicine taken by mouth that helps lower high blood pressure.” NCT07231978 ↗
5

“Drug: prazosin hydrochloride” NCT03221751 ↗

“Drug: Prazosin Hydrochloride” NCT04721353 ↗

“Drug: prazosin hydrochloride” NCT00890643 ↗

“Drug: prazosin hydrochloride” NCT02266329 ↗

“Drug: Prazosin Hydrochloride” NCT01999530 ↗

Known as T.Prazosin (sun pharma) “T.Prazosin (sun pharma)” NCT00753064 ↗
Known as 哌唑嗪 “α1 受体阻滞剂(哌唑嗪)预防自闭症谱系障碍” PMID 38154074 ↗ Sep 2023
Action Inhibit “antagonizes NE effects at brain postsynaptic alpha-1 adrenoreceptors.” PMID 19700947 ↗ Sep 2009
Route Oral “taken orally” NCT00183430 ↗